Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy.

Brachytherapy Hotspot Image-guided PET/TDM cervical cancer

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 18 03 2020
revised: 04 05 2020
accepted: 06 05 2020
entrez: 22 5 2020
pubmed: 22 5 2020
medline: 22 5 2020
Statut: epublish

Résumé

Areas of high uptake on pre-treatment For each patient, a rigid registration of the CT from the pre-treatment PET/CT with the radiotherapy planning CT was performed using 3D Slicer Forty-two patients with recurrence after chemoradiotherapy (CRT) for LACC were matched to 42 patients without recurrence. Mean ± standard deviation follow-up was 26 ± 11 months. In the recurrence group, V1 was not included in the CTV HR and not covered by the 85 Gy isodose in 17/42 patients (41%) (1/20 with pelvic recurrence and 16/22 with distant recurrence) and not by the 80 Gy isodose in 7/42 patients (17%) (all with distant recurrence). In the non-recurrence group, V1 was not included in CTV HR and not covered by the 85 Gy isodose in 3 patients only (7%). The hotspots coverage by the 85 Gy isodose was significantly better in patients who did not recur, but only when compared to patients with distant relapse (p < 0.0001). Suboptimal dosimetric coverage of high FDG uptakes on pretherapeutic PET could be associated with an increased risk of recurrence.

Identifiants

pubmed: 32435702
doi: 10.1016/j.ctro.2020.05.004
pii: S2405-6308(20)30039-2
pmc: PMC7229342
doi:

Types de publication

Journal Article

Langues

eng

Pagination

50-59

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 The Author(s).

Références

IEEE Trans Med Imaging. 2003 Jan;22(1):120-8
pubmed: 12703765
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):310-319
pubmed: 31682968
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194401
Brachytherapy. 2016 Jul-Aug;15(4):456-462
pubmed: 27180129
Sci Rep. 2019 Oct 17;9(1):14925
pubmed: 31624321
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):189-96
pubmed: 15978745
AJR Am J Roentgenol. 2018 Nov;211(5):1112-1121
pubmed: 30207790
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Br J Radiol. 2019 May;92(1097):20190089
pubmed: 30912959
J Nucl Med. 2016 Jul;57(7):1033-9
pubmed: 26966161
Int J Gynecol Cancer. 2013 Jul;23(6):1104-10
pubmed: 23792605
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):91-6
pubmed: 17189066
BMC Cancer. 2017 Dec 06;17(1):825
pubmed: 29207964
Radiat Oncol. 2016 Mar 12;11:39
pubmed: 26968827
Radiat Oncol. 2018 May 2;13(1):81
pubmed: 29716617
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Head Neck. 2017 Jun;39(6):1155-1165
pubmed: 28263422
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50
pubmed: 31637482
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Radiat Oncol. 2018 Apr 12;13(1):65
pubmed: 29650029
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):624-30
pubmed: 16690444
Semin Radiat Oncol. 2018 Jun;28(3):171-177
pubmed: 29933876
IEEE Trans Med Imaging. 2009 Jun;28(6):881-93
pubmed: 19150782
Radiother Oncol. 2011 Jan;98(1):139-42
pubmed: 20971521
Clin Transl Radiat Oncol. 2019 Apr 01;18:60-65
pubmed: 31341977
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):301-8
pubmed: 20116934
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):895-902
pubmed: 30940530
J Contemp Brachytherapy. 2018 Jun;10(3):193-201
pubmed: 30038638
Med Phys. 2017 Jun;44(6):e1-e42
pubmed: 28120467
Eur J Nucl Med Mol Imaging. 2015 May;42(6):858-67
pubmed: 25680400
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):794-801
pubmed: 25245584
Radiother Oncol. 2018 Jun;127(3):370-373
pubmed: 29598835
Radiother Oncol. 2009 Nov;93(2):311-5
pubmed: 19679365
Int J Gynecol Cancer. 2012 Jul;22(6):1031-6
pubmed: 22622949
Lung Cancer. 2012 Jan;75(1):73-6
pubmed: 21782272
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):663-72
pubmed: 21225425
Eur J Nucl Med Mol Imaging. 2018 May;45(5):768-786
pubmed: 29222685
Cancer Radiother. 2020 Apr 1;:
pubmed: 32247688
Radiother Oncol. 2011 May;99(2):137-41
pubmed: 21571386
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Curr Oncol Rep. 2018 Sep 11;20(10):84
pubmed: 30206712
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):348-55
pubmed: 20472347

Auteurs

François Lucia (F)

Radiation Oncology Department, University Hospital, Brest, France.

Vincent Bourbonne (V)

Radiation Oncology Department, University Hospital, Brest, France.

Dorothy Gujral (D)

Clinical Oncology Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Hammersmith, London, UK.
Department of Cancer and Surgery, Imperial College London, London, UK.

Gurvan Dissaux (G)

Radiation Oncology Department, University Hospital, Brest, France.

Omar Miranda (O)

Radiation Oncology Department, University Hospital, Brest, France.

Maelle Mauguen (M)

Radiation Oncology Department, University Hospital, Brest, France.

Olivier Pradier (O)

Radiation Oncology Department, University Hospital, Brest, France.

Ronan Abgral (R)

Nuclear Medicine Department, University Hospital, Brest, France.

Ulrike Schick (U)

Radiation Oncology Department, University Hospital, Brest, France.

Classifications MeSH